Mission

At Vaxcyte, we are driven by our:

Bold Goal

To prevent or treat infections caused by bacterial diseases, such as invasive pneumococcal disease, Group A Strep, periodontitis and Shigella.

Sense of Urgency

Bacterial infections remain one of the greatest public health challenges of our time, with prevention becoming even more critical as antimicrobial resistance increases.

Vast Opportunity

Re-engineering the way complex vaccines are made by leveraging our advanced chemistry platform that goes beyond conventional vaccine development approaches.

Singular Focus

We are on a global mission to engineer high-fidelity vaccines that protect humankind from the consequences of bacterial diseases.

“Not since the 1950s has vaccine innovation been as relevant as it is today. Vaccines are now recognized for the true value they bring in protecting all of us from serious diseases. Pneumococcal vaccines are vital to combating Streptococcus pneumoniae, a serious public health threat exacerbated by increasing antimicrobial resistance.”

Jim Wassil, Executive Vice President and Chief Operating Officer

Image for Pushing the Boundaries of What's Possible

Eliminating Invasive Bacterial Infections

Despite current efforts, bacterial infectious diseases continue to receive inadequate attention. The global incidence of pneumococcal disease remains high, driven in part by emerging serotypes not covered by currently available vaccines. Our site-specific, carrier-sparing platform allows us to engineer broader-spectrum pneumococcal conjugate vaccines (PCVs) that we believe could enable our PCV candidates to surpass the coverage of other pneumococcal vaccines and provide a greater spectrum of coverage while maintaining robust effectiveness.

A Cause Befitting Our Technology

When we began this mission over a decade ago, we set out to make a meaningful difference in protecting humankind from the consequences of bacterial diseases like invasive pneumococcal disease. We determined early on that developing a more broadly protective PCV was the highest and best use of our technology, and we believe our unique platform has enabled us to develop one of the most complex biologics ever attempted.

Grant Pickering

Chief Executive Officer, Director and Co-Founder

With our novel technology, we believe we can go beyond traditional vaccine approaches when it comes to addressing bacterial diseases and we are exploring preventing or treating pathogens, such as Group A Strep and Shigella, for which no vaccines currently exist.

Jeff Fairman

Vice President of Research and Co-Founder

We are working to develop vaccines that improve upon those that are available or forge into new areas where prevention has not been possible. It’s more than incremental change. To us, it’s a chance to markedly expand the role vaccines play in treating global health.

Andrew Guggenhime

President and Chief Financial Officer